AI Article Synopsis
- Existing antithrombotic drugs can cause bleeding, creating a need for new options with better effectiveness and fewer side effects.* -
- This study used a zebrafish model to test Brevianamide F, revealing it reduces platelet aggregation, increases circulating platelets, and improves blood flow and heart rate.* -
- The research found that Brevianamide F may work by influencing the MAPK signaling pathway and coagulation processes, offering insights for future thrombosis treatments.*
Article Abstract
Existing antithrombotic drugs have side effects such as bleeding, and there is an urgent need to discover antithrombotic drugs with better efficacy and fewer side effects. In this study, a zebrafish thrombosis model was used to evaluate the antithrombotic activity and mechanism of Brevianamide F, a deep-sea natural product, with transcriptome sequencing analysis, RT-qPCR analysis, and molecular docking. The results revealed that Brevianamide F significantly attenuated the degree of platelet aggregation in the thrombus model zebrafish, leading to an increase in the number of circulating platelets, an augmentation in the return of blood to the heart, an elevated heart rate, and a significant restoration of caudal blood flow velocity. Transcriptome sequencing and RT-qPCR validation revealed that Brevianamide F may exert antithrombotic effects through the modulation of the MAPK signaling pathway and the coagulation cascade reaction. Molecular docking analysis further confirmed this result. This study provides a reference for the development of therapeutic drugs for thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509512 | PMC |
| http://dx.doi.org/10.3390/md22100439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medication Use in People Aged 90 Years and Older: A Nationwide Study.
J Am Med Dir Assoc
January 2025
EPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France; Université de Versailles Saint-Quentin-en-Yvelines, France.
Objective: We aimed to describe the medications prescribed to people aged ≥90 years.
Design: A cohort study was performed using data from the year 2022.
Setting And Participants: Using data from the French National Health Data System, people aged ≥90 years affiliated with the general insurance scheme were included.
Low Attainment of Treatment Targets for Cardiovascular Risk Factors in Indonesian Adults With Established Coronary Artery Disease.
J Eval Clin Pract
February 2025
Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Rationale: Established coronary artery disease (CAD) patients are at increased risk for recurrence of cardiovascular events and mortality due to non-attainment of recommended risk factor control targets.
Objective: We aimed to evaluate the attainment of treatment targets for risk factor control among CAD patients as recommended in the Indonesian CVD prevention guidelines.
Methods: Patients were consecutively recruited from the Makassar Cardiac Center at Wahidin Sudirohusodo Hospital, Indonesia.
Antithrombotic therapy impact on patency and bleeding complications of arteriovenous graft placement in dialysis patients.
Vasa
January 2025
Department of Vascular Surgery, Larissa University Hospital, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Arteriovenous grafts (AVG) can be the only bailout solution for patients who require kidney replacement therapy but are unsuitable for arteriovenous fistula (AVF) creation. Currently, high-level evidence on the effectiveness and safety of antithrombotic therapy in AVG patients is scarce. Following the PICO (patient; intervention; comparator; outcome) model and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a data search of the English literature in PubMed, SCOPUS, Central Cochrane was conducted, until March 1st, 2023 (PROSPERO Protocol Number: CRD42023401785).
View Article and Find Full Text PDFIntegration of a specialist pharmacist-led multidisciplinary team in primary care: preventing strokes in people with atrial fibrillation across North East London.
BMJ Open Qual
January 2025
Department of Pharmacy, Barts Health NHS Trust, London, UK.
Public Health England outlines a national ambition of anticoagulating 90% of eligible patients with atrial fibrillation (AF) by 2029. In 2019/2020, two out of three boroughs reviewed in this study were in the bottom 10% of boroughs compared with others within England. Stroke National Audit data for these three boroughs from 2019 to 2020 identified that in patients with known AF admitted to hospital with strokes, 37% were not anticoagulated.
View Article and Find Full Text PDFParametric finite element modeling of reinforced polymeric leaflets for improved durability.
J Mech Behav Biomed Mater
January 2025
School of Materials Science and Engineering, Colorado State University, 700 Meridian Ave, Fort Collins, 80523, CO, USA. Electronic address:
Hyaluronic acid-enhanced polyethylene polymeric TAVR shows excellent in vivo anti-calcific, anti-thrombotic, and in vitro hydrodynamic performance. However, during durability testing, impact wear and fatigue cause early valve failure. Heart valve durability can be improved by strengthening the leaflet with fiber reinforcement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!